NCT04361812View on ClinicalTrials.gov

Comparison of Pharmacokinetics and Safety of HS632 and Xolair® With a Single Injection

PHASE1UnknownINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

October 15, 2020

Primary Completion Date

December 31, 2021

Study Completion Date

December 31, 2021

Conditions
Similarity of Pharmacokinetics and Safety
Interventions
DRUG

HS632

Subcutaneous injection of HS632

DRUG

Omalizumab (Xolair®)

Subcutaneous injection of Omalizumab Xolair®)

Trial Locations (1)

200040

Anhui Peng, Shanghai

Sponsors
All Listed Sponsors
lead

BioRay Pharmaceutical Co., Ltd.

INDUSTRY